about
Characterizing the anti-HIV activity of papuamide AMAP 30: a new inhibitor of HIV-1 infection and replicationA new class of anti-HIV agents: GAP31, DAPs 30 and 32CD4 antigen-based antireceptor peptides inhibit infectivity of human immunodeficiency virus in vitro at multiple stages of the viral life cycleHuman immunodeficiency virus type 1 (HIV-1) inhibition, DNA-binding, RNA-binding, and ribosome inactivation activities in the N-terminal segments of the plant anti-HIV protein GAP31Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus proteaseT30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1The human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein zinc ejection activity of disulfide benzamides and benzisothiazolones: correlation with anti-HIV and virucidal activitiesHuman immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation.The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonismStoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1Inhibition of HIV-1 endocytosis allows lipid mixing at the plasma membrane, but not complete fusion.Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide databaseDevelopment of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.The triple combination indinavir-zidovudine-lamivudine is highly synergistic.Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workersHuman immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter.Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection.Antagonistic interaction of HIV-1 Vpr with Hsf-mediated cellular heat shock response and Hsp16 in fission yeast (Schizosaccharomyces pombe)Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency virusesAnti-vpr activities of heat shock protein 27.The auto-regulation model: a unified concept of how HIV regulates its infectivity, pathogenesis and persistence.Probing Mercaptobenzamides as HIV Inactivators via Nucleocapsid Protein 7.Downregulation of cell-surface CD4 expression by simian immunodeficiency virus Nef prevents viral super infection.HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism.HIV-1-Induced Small T Cell Syncytia Can Transfer Virus Particles to Target Cells through Transient ContactsSpecific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine.Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individualsQuantitation of human immunodeficiency virus type 1 infection kinetics.Blocking of human immunodeficiency virus infection depends on cell density and viral stock agePotent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsActivation of a beta-galactosidase recombinant provirus: application to titration of human immunodeficiency virus (HIV) and HIV-infected cells.Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptaseRev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotesAnalysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivationIsolation and characterization of niphatevirin, a human-immunodeficiency-virus-inhibitory glycoprotein from the marine sponge Niphates erecta.
P2860
Q24645399-A9D55768-FE23-491C-B342-D375633E609AQ28323531-9B349323-1905-4E37-A591-D5D56BD222E8Q28333791-95D69D83-79F6-4D66-95EA-7505AC56E8ECQ28359667-C50CBDC8-12CB-41F3-AF55-6E58ECA17E9FQ28367618-20C762FA-259F-47E4-A64D-04965BFD400FQ28368080-8BCAD297-92EE-4EAC-8A54-54BF619C4856Q28378782-721D10F8-5706-4049-8D46-538559FCE69FQ28379466-4CD235E1-82D4-4CB1-9CFD-AFEB1D27BF4EQ28646878-740B9198-55F2-42F3-81B2-FBF96528DE41Q28742774-CB0EB1AF-21B8-4E18-BBB5-476FD0D32F0EQ30447936-8D21B1EF-4969-4099-BCF7-649213B0ED3DQ30507959-4D775B42-4C5F-418E-9710-282573E6D1C7Q33676425-D5873D56-8099-42FF-841B-2D3E152AF575Q33962846-3AC91954-3885-4D89-A87F-1AAE5C054520Q33979237-B4468762-F11B-4F09-A16C-17082C32D927Q34151491-723DEF1C-1BF9-4769-B784-971B72BEB3DAQ34338761-A1365240-75B5-405E-BACA-7C32633C0E80Q34757765-E5CB71DA-C186-4F05-A076-B0075A6D3D72Q35137168-EE14A422-077F-4656-B4A4-B81532855BCCQ35189274-93597C79-AED8-4C3B-89A7-56B2C8AE5306Q35689843-6D484A00-8047-4A99-83D4-6F039FAFD173Q35863198-2DF49332-ABAE-4CDF-A40B-1D65BA528B30Q35868679-1E6623C0-7E05-44D7-9129-9D340C84E59BQ36055538-EF2DEE91-8FB2-4787-80E4-9288A7BE5E09Q36342362-6419F47B-0B13-46DE-8D4C-BE99AEC8853CQ36361799-AABF0279-EDBF-470A-91CA-E5C9D932E997Q36400607-420164A5-E48E-42F9-83F3-1ADB4DDC09C9Q36403454-771AC322-6AC0-4AA8-A0BC-637F5D6E9C40Q36518384-8DC8BB44-234E-4C33-8EA9-B1F462C2CB57Q36635175-E6FEFE51-1529-4B3A-BCA3-445D346BC2A4Q36638137-F8C4E5DC-042D-4BED-8CF5-21B55F61D3ECQ36641676-5B97C753-2292-4475-8D10-24AA0CDFCEF5Q36686530-2E3D7124-CCFD-4A94-9687-EADF18365A47Q36695580-AE4C1A42-F0AC-4E9D-B7DA-BEBA5ACD3E7CQ36703042-272BB277-454D-4584-B014-334FA564F033Q36806944-E2540EFA-B185-443E-A29C-5795278A369DQ36810415-C3A22EF1-E2FD-41AE-B63B-EA0866593562Q36823499-AAA8540F-C511-4C19-9D4F-DD487F2EB379Q36828521-808980EF-DE23-4E6E-8CB5-75F8BB789048Q36857413-23C0A207-002A-4A69-94B1-29A498D63A49
P2860
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Quantitative infectivity assay for HIV-1 and-2.
@en
Quantitative infectivity assay for HIV-1 and-2.
@nl
type
label
Quantitative infectivity assay for HIV-1 and-2.
@en
Quantitative infectivity assay for HIV-1 and-2.
@nl
prefLabel
Quantitative infectivity assay for HIV-1 and-2.
@en
Quantitative infectivity assay for HIV-1 and-2.
@nl
P356
P1433
P1476
Quantitative infectivity assay for HIV-1 and-2.
@en
P2093
Fischinger PJ
P2888
P304
P356
10.1038/332469A0
P407
P577
1988-03-01T00:00:00Z
P6179
1016439845